University Of Pittsburgh
Boston Children’s tops U.S. News & World Report’s list for 6th year
VIDEO: Head and neck cancer landscape changing as incidence of HPV-positive disease increases
Hematology/Oncology Pharmacy Association honors 2019 fellows
Blended treatment for depression, heart failure improves quality of life
One approach does not fit all in ACL reconstruction
What should orthopedic practices and departments do to eliminate sexual harassment?

While the faces of orthopedic providers now more closely reflect the diverse patient populations they serve, continued efforts must be made to realize the potential benefit afforded by such diversity of perspective. Sexual harassment, as with all forms of harassment, undermines any prospect of creating a work environment of mutual respect, where all persons can share their unique talents to accomplish our mission of excellent patient care. Communication is central in preventing sexual harassment and, should an incident occur, it should be promptly investigated. Departments and practices should establish an explicit code of conduct and policies related to a harassment-free workplace and non-retaliatory reporting. It is essential to set departmental and organizational expectations about zero tolerance. Of equal or perhaps greater importance, a culture of inclusion and professionalism must be cultivated, starting from the top. Leaders and those in positions of responsibility must be champions of respect, serving as conscientious exemplars and demanding that other team members adhere to such a code of conduct. There can be no double standard for high-performing physicians; to the contrary, those in positions of power must be particularly cognizant of how those without such influence may be reluctant to voice grievances or suggestions. In Pittsburgh, and in the spirit of Mr. Rogers, we strive to be good neighbors. Our (orthopedic) neighborhood will only thrive if each of us feels respected and encouraged to share the best of what we each possess.
TPS1103 aims to extend PFS in HER2-positive breast cancer

Adam Brufsky, MD, PhD, FACP, is a professor of medicine at the University of Pittsburgh School of Medicine. He also serves as associate division chief for the division of hematology/oncology in the University of Pittsburgh School of Medicine's Department of Medicine, medical director of the Magee-Women's Cancer Program, associate director for clinical investigations at UPMC Hillman Cancer Center and codirector of the Comprehensive Breast Cancer Center. Brufsky spoke with Healio about the TPS1103 trial, which will examine the addition of palbociclib to pertuzumab plus trastuzumab and an aromatase inhibitor in patients with HER2-positive, HR-positive breast cancer.
Children struggle with limited options during Ebola outbreaks
Drug prices rise twice as fast during shortages
Results at 20-year follow-up support nonoperative ACL rupture treatment
At 2 decades after patients in a study with ACL rupture underwent operative or nonoperative treatment, researchers found no significant differences between the groups for the presence of knee osteoarthritis, functional outcomes and any meniscectomy surgery, according to results published in The American Journal of Sports Medicine.